MX2022003301A - Derivado de interleucina-2. - Google Patents
Derivado de interleucina-2.Info
- Publication number
- MX2022003301A MX2022003301A MX2022003301A MX2022003301A MX2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A
- Authority
- MX
- Mexico
- Prior art keywords
- derivative
- cysteine residue
- closed
- closed module
- wild
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describe un derivado de IL-2. Al introducir por lo menos un residuo de cisteína en base a IL-2 de tipo silvestre, el plano de enlace del derivado de IL-2 y la subunidad del receptor a se bloquea parcialmente o completamente, mientras que la afinidad del derivado de IL-2 al complejo de subunidades del receptor ß y ? se retiene básicamente. También se describe un complejo, que comprende: un derivado de IL-2, que se introduce con un tercer residuo de cisteína en base a IL-2 de tipo silvestre; y un módulo de bloqueo, que tiene o se introduce con un cuarto residuo de cisteína; en donde el tercer residuo de cisteína en el derivado de IL-2 y el cuarto residuo de cisteína en el módulo de bloqueo son capaces de formar un enlace de disulfuro intermolecular, para de esta manera formar un complejo del derivado de IL-2 y el módulo de bloqueo; y en donde el plano de enlace del derivado de IL-2 y la subunidad del receptor a se bloquea parcialmente o completamente, mientras que la afinidad del derivado de IL-2 al complejo de subunidades del receptor ß y ? se retiene básicamente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911302355.5A CN111018961B (zh) | 2019-12-17 | 2019-12-17 | 白介素-2衍生物 |
PCT/CN2020/070748 WO2021120350A1 (zh) | 2019-12-17 | 2020-01-07 | 白介素-2衍生物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003301A true MX2022003301A (es) | 2022-04-12 |
Family
ID=70210189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003301A MX2022003301A (es) | 2019-12-17 | 2020-01-07 | Derivado de interleucina-2. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220363731A1 (es) |
EP (1) | EP4023666A4 (es) |
JP (1) | JP2023514003A (es) |
KR (1) | KR20220113918A (es) |
CN (4) | CN114437198A (es) |
AU (1) | AU2020406768A1 (es) |
BR (1) | BR112022003712A2 (es) |
CA (1) | CA3151681A1 (es) |
GB (1) | GB2604238A (es) |
MX (1) | MX2022003301A (es) |
WO (1) | WO2021120350A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022011893A (es) | 2020-03-31 | 2022-10-18 | Hanmi Pharm Ind Co Ltd | Nuevos analogos de il-2 inmunoestimuladores. |
EP4139341A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
TW202210502A (zh) | 2020-06-03 | 2022-03-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 新穎il-2序列及其用途 |
CN114380919A (zh) | 2020-10-18 | 2022-04-22 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
CN114369153A (zh) * | 2020-10-18 | 2022-04-19 | 北京志道生物科技有限公司 | 一种白介素-2突变体 |
WO2023046156A1 (en) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Il-2 variants and fusion proteins thereof |
CN114306576A (zh) * | 2022-01-11 | 2022-04-12 | 北京志道生物科技有限公司 | 一种防止il-2衍生物蛋白复合体聚集及非共价连接蛋白亚基脱落的制剂 |
CN114349843B (zh) * | 2022-01-18 | 2024-05-14 | 浙江博锐生物制药有限公司 | 白细胞介素-2衍生物及其制备方法和应用 |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
WO2024104444A1 (zh) * | 2022-11-17 | 2024-05-23 | 南通壹宸生物医药科技有限公司 | Il-2突变体及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1208345C (zh) * | 2002-07-23 | 2005-06-29 | 重庆大学 | 重组人白细胞介素-2的三突变体及制备方法 |
AU2007271398B2 (en) | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
SI2673294T1 (sl) | 2011-02-10 | 2016-08-31 | Roche Glycart Ag | Mutirani polipeptidi interlevkina-2 |
NZ728175A (en) * | 2014-08-11 | 2023-03-31 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
WO2019028425A1 (en) * | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
WO2019091384A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
CA3086842A1 (en) * | 2017-12-27 | 2019-07-04 | Kyowa Kirin Co., Ltd. | Il-2 variant |
EP3773680A1 (en) * | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Division A/S | Il-2 conjugates |
CA3136992A1 (en) * | 2019-05-24 | 2020-12-03 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
-
2019
- 2019-12-17 CN CN202210110228.0A patent/CN114437198A/zh active Pending
- 2019-12-17 CN CN201911302355.5A patent/CN111018961B/zh active Active
- 2019-12-17 CN CN202210176105.7A patent/CN114524873A/zh active Pending
- 2019-12-17 CN CN202210110617.3A patent/CN114478743A/zh active Pending
-
2020
- 2020-01-07 MX MX2022003301A patent/MX2022003301A/es unknown
- 2020-01-07 CA CA3151681A patent/CA3151681A1/en active Pending
- 2020-01-07 BR BR112022003712A patent/BR112022003712A2/pt unknown
- 2020-01-07 EP EP20901536.1A patent/EP4023666A4/en active Pending
- 2020-01-07 US US17/771,032 patent/US20220363731A1/en active Pending
- 2020-01-07 WO PCT/CN2020/070748 patent/WO2021120350A1/zh unknown
- 2020-01-07 AU AU2020406768A patent/AU2020406768A1/en active Pending
- 2020-01-07 KR KR1020227008663A patent/KR20220113918A/ko unknown
- 2020-01-07 GB GB2201999.6A patent/GB2604238A/en active Pending
- 2020-01-07 JP JP2022535594A patent/JP2023514003A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114437198A (zh) | 2022-05-06 |
CN111018961A (zh) | 2020-04-17 |
EP4023666A4 (en) | 2023-03-22 |
CN114524873A (zh) | 2022-05-24 |
CN111018961B (zh) | 2022-03-18 |
CA3151681A1 (en) | 2021-06-24 |
EP4023666A1 (en) | 2022-07-06 |
GB202201999D0 (en) | 2022-03-30 |
US20220363731A1 (en) | 2022-11-17 |
GB2604238A (en) | 2022-08-31 |
JP2023514003A (ja) | 2023-04-05 |
WO2021120350A1 (zh) | 2021-06-24 |
KR20220113918A (ko) | 2022-08-17 |
AU2020406768A1 (en) | 2022-03-03 |
BR112022003712A2 (pt) | 2022-10-11 |
CN114478743A (zh) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003301A (es) | Derivado de interleucina-2. | |
PH12016502358A1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
MX2021009352A (es) | Compuestos de fijacion al receptor de il -2. | |
MX2020014027A (es) | Dise?o de novo de mimeticos de interleucina potentes y selectivos. | |
TR201809594T4 (tr) | Fikstür. | |
NZ722668A (en) | Anti-her3 antibody-drug conjugate | |
MY178760A (en) | Monocyclic pyridine derivative | |
TWD202667S (zh) | 閘道器 | |
MX2020010657A (es) | Derivados de oxadiazolina. | |
WO2020081410A3 (en) | Radioligands for imaging the lpa1 receptor | |
WO2018195521A3 (en) | Magnetic quick-release mechanism | |
ZA202106602B (en) | Claudin 6 antibodies and uses thereof | |
MX2021005593A (es) | Miméticos de interleucina dividida y sus usos. | |
WO2020131586A3 (en) | Methods for identifying neoantigens | |
MX2018001791A (es) | Cabeza de soldadura. | |
EP3911315A4 (en) | SOLID MICRONIZED MELATONIN COMPOSITION | |
JOP20130157B1 (ar) | مركب للوقاية من الصداع | |
GB202013962D0 (en) | Immunotherapy composition | |
EP3901147A4 (en) | ACYLAMINO BRIDGE HETEROCYCLIC COMPOUND, ASSOCIATED COMPOSITION AND USE | |
MY198519A (en) | Composition for browning inhibition and use of same | |
SG11201900713XA (en) | Method of preparing coal ash | |
MX2022003764A (es) | Derivados de mentol y usos de los mismos. | |
MX2021015473A (es) | Nuevo anticuerpo específico para cthrc1 y su uso. | |
EP3557005B8 (en) | Seal assembly with shield for gas turbine engines | |
EP3793360A4 (en) | METHODS AND COMPOSITIONS FOR SUBSTITUTED 2,5-DICETOPIPERAZINE ANALOGS |